To develop a treatment for Duchenne muscular dystrophy (DMD), a common myopathic disease in children caused by loss of a functional dystrophin protein, the inhibitory domain of myostatin propeptide was fused with the second extracellular loop of CD63, which significantly improved its serum stability and delivery efficiency. This evidence concerns the gene DMD and Duchenne muscular dystrophy.